Literature DB >> 9621393

Endogenous opioids and smoking: a review of progress and problems.

O F Pomerleau1.   

Abstract

The present report examines efforts to elucidate the role of opioid mechanisms in the reinforcement of smoking. A number of approaches have been used to evaluate nicotine-opioid interactions. Opiate agonists such as heroin or methadone have been found to increase cigarette smoking reliably in humans, and morphine has been shown to increase the potency and efficacy of nicotine in rats. There is also an extensive literature documenting the nicotine-stimulated release of endogenous opioids in various brain regions involved in the mediation of opiate reinforcement. Blockade studies using opioid antagonists have not been as conclusive. Although animal models have demonstrated commonalities between nicotine withdrawal and the opiate abstinence syndrome, including reversibility by morphine, and although the impact of nicotine on certain response systems such as respiratory reflexes has clearly been shown to involve opioid mediation, attempts to demonstrate opioid modulation for the key indicators of smoking reinforcement--cigarette consumption and nicotine self-administration--have been fraught with difficulty. Resolution of the apparent contradictions will require taking into account: (a) the biphasic properties of nicotine-opioid effects at higher doses and anti-opioid effects at lower doses; (b) the contributions of the opioid receptor populations--mu, kappa, sigma--stimulated at various dose levels; (c) the possibility that endogenous-opioid activity is entrained primarily during the acquisition or re-acquisition of nicotine self-administration; (d) the possibility that the endogenous opioid response does contribute to nicotine reinforcement but only as a delimited component of the neuroregulatory cascade of nicotine; and (e) the possibility that opioids contribute primarily to nicotine reinforcement under special conditions such as stress. Taking these considerations into account should allow studies on endogenous opioid effects to begin to do justice to the complexity of both smoking behavior and the actions of nicotine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9621393     DOI: 10.1016/s0306-4530(97)00074-7

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  19 in total

1.  Cigarette smoking, illicit drug use, and routes of administration among heroin and cocaine users.

Authors:  P T Harrell; R C Trenz; M Scherer; L R Pacek; W W Latimer
Journal:  Addict Behav       Date:  2012-01-17       Impact factor: 3.913

2.  Attenuated beta endorphin response to acute stress is associated with smoking relapse.

Authors:  Darcy Shaw; Mustafa al'Absi
Journal:  Pharmacol Biochem Behav       Date:  2008-04-03       Impact factor: 3.533

3.  Naltrexone attenuation of conditioned but not primary reinforcement of nicotine in rats.

Authors:  Xiu Liu; Matthew I Palmatier; Anthony R Caggiula; Alan F Sved; Eric C Donny; Maysa Gharib; Sheri Booth
Journal:  Psychopharmacology (Berl)       Date:  2008-09-21       Impact factor: 4.530

4.  Acute nicotine changes dynorphin and prodynorphin mRNA in the striatum.

Authors:  Raffaella Isola; Hailin Zhang; Gopi A Tejwani; Norton H Neff; Maria Hadjiconstantinou
Journal:  Psychopharmacology (Berl)       Date:  2008-09-21       Impact factor: 4.530

5.  Genetic ancestry as an effect modifier of naltrexone in smoking cessation among African Americans: an analysis of a randomized controlled trial.

Authors:  Adam Bress; Rick Kittles; Coady Wing; Stanley E Hooker; Andrea King
Journal:  Pharmacogenet Genomics       Date:  2015-06       Impact factor: 2.089

6.  Effects of the opioid receptor antagonist naltrexone on smoking and related behaviors in smokers preparing to quit: a randomized controlled trial.

Authors:  Andrea King; Dingcai Cao; Lingjiao Zhang; Sandra Yu Rueger
Journal:  Addiction       Date:  2013-07-12       Impact factor: 6.526

Review 7.  OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models.

Authors:  Stephen D Mague; Julie A Blendy
Journal:  Drug Alcohol Depend       Date:  2010-01-13       Impact factor: 4.492

8.  Nicotine-specific and non-specific effects of cigarette smoking on endogenous opioid mechanisms.

Authors:  Emily B Nuechterlein; Lisong Ni; Edward F Domino; Jon-Kar Zubieta
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2016-04-17       Impact factor: 5.067

Review 9.  Tobacco/nicotine and endogenous brain opioids.

Authors:  Yue Xue; Edward F Domino
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-12-23       Impact factor: 5.067

10.  Blunted opiate modulation of hypothalamic-pituitary-adrenocortical activity in men and women who smoke.

Authors:  Mustafa al'Absi; Lorentz E Wittmers; Dorothy Hatsukami; Ruth Westra
Journal:  Psychosom Med       Date:  2008-09-16       Impact factor: 4.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.